Author(s): Guenther LC, Kunynetz R, Lynde CW, Sibbald RG, Toole J, Vender R, Zip C
BACKGROUND: Acitretin has been used for the treatment of severe psoriasis for over 20 years.
OBJECTIVE: The current project was conceived to optimise patient care by recognising the role acitretin can play in the treatment of patients with psoriasis and those with other disorders of keratinisation.
METHODS: A literature review was conducted to explore the role of acitretin and to assess its value for dermatologic disorders other than severe psoriasis. A panel of Canadian dermatologists developed a clinical pathway using a case-based approach, focusing on specific patient features.
RESULTS: The clinical pathway covers plaque psoriasis with hyperkeratotic plantar disease, palmoplantar pustulosis, hyperkeratotic hand dermatitis, lichen planus, lamellar ichthyosis, and hidradenitis suppurativa.
CONCLUSION: The recommendations in our clinical pathway reflect the current use of acitretin in Canada for severe psoriasis and other disorders of keratinisation.
Dermatology Journal and/or Publisher
Journal Name: Journal of cutaneous medicine and surgery
Journal Abbreviation: J Cutan Med Surg
Journal Date Published:
National Center for Biotechnology Information
Article Source: http://www.ncbi.nlm.nih.gov/pubmed/28952335
Lasted Revision: 2017-11-07
Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for Hidradenitis suppurativa (HS).